x
ServiziMenu principaleHome
You are here: Home > Educational Opportunities > Future Events > Refresher course on prostate cancer
Share on Share on Facebook Twitter Share on Linkedin Share on WhatsApp Share on Instagram Share by email Print this page

Description

Chairs:  G. Baciarello, IT – B. Šeruga, SI

The refresher course on prostate cancer has been designed for medical and clinical oncologists with the aim to provide an update on the -state of-the art therapeutic options as well as an overview of the latest advances in the field. Practical training will be offered in the frame of clinical case presentations, prepared and presented by participants and discussed with the faculty. 

Attendance to the course is limited and by application only. Priority will be given to applicants who have attended a previous ESO masterclass. 

LEARNING OBJECTIVES 

  • Update on the latest advances in screening and diagnostic procedures 
  • Update on the latest advances and on the state-of- the-art treatment options 
  • Learn about the management of specific situations 
  • Understand the pathology and molecular characteristics of prostate cancer 
  • Learn about the future development in the treatment of prostate cancer 
  • Debate controversies and challenges in prostate cancer 
  • Improve practical skills in multidisciplinary management and follow-up of patients with prostate cancer 

Information

OFFICIAL LANGUAGE 

The official language will be English. No translation will be available. 

CME ACCREDITATION 

An application to the European Accreditation Council for Continuing Medical Education (EACCME) will be submitted to obtain CME credits for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net
Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. 

ESCO - The ESO College 

 
Being selected to take part in this ESO activity gives participants eligibility to enrol in ESCO - the College of the European School of Oncology. 
This event also enables ESCO students to earn ESCO credits and therefore access more ESCO benefits. 
Full and active participation in the event earns participants 9 ESCO credits. 
Visit www.ESCO.org for more information on how to join ESCO. 

PARTICIPATION 

Attendance is limited to 30 participants and admittance is by competitive application only. Priority will be given to applicants who have attended an ESO masterclass. 

Applicants should meet the following profile: 

  • Age between 30 and 45 years 
  • At least 2-3 years’ experience in medical oncology 
  • Fluency in English 

Successful applicants are granted free registration. 

Accommodation at the course venue for arrival on 24thMay and departure on the 26thMay will be provided to participants not residing in the Ljubljana area. 

ORGANISING SECRETARIAT 

Mariachiara Deleo
European School of Oncology (ESO)
Via Turati 29
IT- 20121 Milan

ph  +39 335 181 4541
email: mdeleo@eso.net

Dolores Knupfer 
European School of Oncology (ESO) 
Via Vicenzo Vela 6 
CH- 6500 Bellinzona 
 
ph +41 91 820 09 52 
e-mail: dknupfer@eso.net 

Application

APPLICATION DEDLINE: 22 March 2024

Interested candidates should apply online providing:

  • Application template
  • Abstract
  • Letter describing motivation for attending
  • Short CV (template CV) with the list of publications (if the list of publication is not provided, it will be assumed that no articles have been published)

If you are a past ESO Masterclass participant, you only need to submit the application template and abstract.

ABSTRACT

Applicants are requested to submit an abstract describing a clinical case related to prostate cancer on one of the following categories:

  • Localized prostate cancer (to treat or not to treat)
  • Locally-advanced prostate cancer
  • Biochemical recurrence/Persistent PSA
  • Advanced castrate sensitive prostate cancer
  • Advanced castrate resistant prostate cancer

A selected number of admitted participants will have the opportunity to present their clinical case in the format of a clinical grand round discussion with the chairs, other faculty members and participants within plenary tumour board sessions in the programme. The application outcome will be notified by e-mail by the 12th April.

 

 

Programme

24 May

19:00Registration at hotel
20:00Free evening

25 May

8:15Transfer to course venue
8:45Welcome address, general introduction
Giulia Baciarello, IT - Fedro Alessandro Peccatori, IT - Bostjan Seruga, SI
9:00Prostate cancer pathology: recent advances and controversies
Metka Volavšek, SI
9:20Discussion
9:30Molecualr biology of early and advanced prostate cancer
Giulia Baciarello, IT
9:50Germline and somatic molecular testing in prostate cancer
Srdjan Novakovic, SI
10:00Discussion
10:10Challenges with conventional imaging methods for prostate cancer
Giuseppe Petralia, IT
10:30Coffee break
10:45Louis Denis Memorial Lecture: Evolving paradigm of prostate cancer screening
Miha Pukl, SI
11:00Discussion
11:10Molecular imaging in early and advanced prostate cancer
Andrea Farolfi, IT
11:30Debate: Integration of new imaging techniques into clinical practice for prostate cancer: exploring advantages and pitfalls
Giulia Baciarello, IT - Berardino De Bari, CH - Simon Hawlina, SI
11:45Active surveillance for prostate cancer
Miha Pukl, SI
12:00Discussion
12:15Lunch
14:00Surgical treatment of prostate cancer
Simon Hawlina, SI
14:20Discussion
14:30Radiotherapy for localised prostate cancer
Berardino De Bari, CH
14:50Discussion
15:00Systemic therapy in localized and locally advanced prostate cancer
Bostjan Seruga, SI
15:20Discussion
15:30Current treatment for biochemical recurrence/PSA persistence:
Berardino De Bari, CH
15:50Discussion
16:00Coffee break
16:20Debate: Optimizing treatment strategies for patients with biochemical recurrence/PSA persistence in prostate

 
 16:20Medical oncologist’s perspective
Bostjan Seruga, SI
 16:30Urologist’s perspective
Simon Hawlina, SI
 16:40Radiotherapist ‘s perspective
Berardino De Bari, CH
16:50Discussion
17:00Tumor board: Selected clinical cases presented by participants and discussed with the faculty
18:00Welcome drink followed by free evening

26 May

8:00Transfer to venue
8:30Management of metastatic castrate-sensitive prostate cancer
Arnoud Templeton, CH
8:50Debate: Oligorecurrent prostate cancer: Medical vs radiation oncologist
Berardino De Bari, CH - Arnoud Templeton, CH
9:10Debate: Sinchronous oligometastatic prostate cancer: Medical vs radiation oncologist
Giulia Baciarello, IT - Berardino De Bari, CH
9:30Discussion
9:50Current Management of metastatic castrate-resistant prostate cancer
Giulia Baciarello, IT
10:00PSMA-based therapies for castrate-resistant prostate cancer
Andrea Farolfi, IT
10:15Introduction to clinical trials in oncology
10:25Discussion
10:35Coffee break
11:00Identification, assessment and management of side effects of systemic therapy
Bostjan Seruga, SI
11:20Discussion
11:30Tumor board: Selected clinical cases presented by participants and discussed with the faculty
12:30Closing remarks
Giulia Baciarello, IT - Fedro Alessandro Peccatori, IT - Bostjan Seruga, SI

Faculty

Giulia Baciarello, San Camillo-Forlanini Hospitals, Genitourinary Oncology Dpt., Rome, IT
Tanja Cufer, University of Ljubljana, Medical Faculty, Ljubljana, SI
Berardino De Bari, Neuchâtel Hospital Network, Dept. of Radiation Oncology, La Chaux-de-Fonds, CH
Andrea Farolfi, Policlinico S.Orsola, PAD 30, Bologna, IT
Simon Hawlina, Ljubljana University Medical Centre, Department of Urology, Ljubljana, SI
Srdjan Novakovic, Institute of Oncology, Department of Molecular Diagnostics, Ljubljana|, SI
Fedro Alessandro Peccatori, European Institute of Oncology, Dept. of Fertility and Procreation in Oncology, Milano, IT
Giuseppe Petralia, European Institute of Oncology - IEO, Radiology Department, Milan, IT
Miha Pukl, Institute of Oncology, Urology Department, Ljubljana|, SI
Bostjan Seruga, Institute of Oncology Ljubljana, Dept. of Medical Oncology, Ljubljana, SI
Arnoud Templeton, St. Claraspital Basel, Oncology Dept, Basel, CH
Metka Volavšek, University of Ljubljana, Institute of Pathology, Faculty of Medicine, Ljubljana, SI